<DOC>
	<DOCNO>NCT00460629</DOCNO>
	<brief_summary>Efforts decrease risk GvHD deplete T cell graft CML patient complicate increased incidence leukemia-relapse . Newer protocols use CD34+ select hematopoietic cell matched-sibling donor subsequent infusion T cell incremental dos treat avoid relapse disease seem promise . In study , try optimize approach prophylactic infusion cytotoxic T cell activate ex-vivo leukemia-associated/specific antigen use peptide-pulsed dendritic cell .</brief_summary>
	<brief_title>Prophylactic Transfer Leukemia-reactive T Cells After Allogeneic Transplantation</brief_title>
	<detailed_description>The conditioning protocol contains : Total Body Irradiation 8-12 Gy ( 4-6 x 2 Gy , 2 x/die ) day -9 to-7 Thiotepa 10 mg/kg ( 2 x 5 mg/kg ) day -5 Fludarabine 200 mg/m2 ( 5 x 40 mg/m2 ) day -6 to-2 ATG Fresenius 25 mg/kg ( 5 x 5 mg/kg ) day -6 to-2 Cyclosporine A 1 mg/kg Day -10 to-3 day 0 CD34+ cell immunomagnetic selection infuse . &gt; 4 x 10e6/kg CD34 cells/kg require . On day 28 , 56 112 transplantation , cytotoxic T cell generate in-vitro infused patient sign acute GvHD . Regular follow-up compromise immune monitor include Tetramer analysis Peptide-reactive T cell</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>age 1860 Ph+ CML HLA A0201 , 0301 , 1101 , B0801 BCRABL b3a2 positive significant comorbidities resistance intolerance imatinib HIV positive blast crisis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Adoptive immunotherapy</keyword>
	<keyword>BCR-ABL reactive T cell</keyword>
	<keyword>Allogeneic Transplantation</keyword>
</DOC>